Patents Represented by Attorney Richard S. Parr

Find this attorney in the Justia Lawyer Directory

  • Fibrinogen receptor antagonists
    Patent number: 6117842
    Abstract: Compounds of this invention have the formula:X--(CH.sub.2).sub.n --C(O)NH--A--C(COOR.sup.5)R.sup.3 R.sup.4or a pharmaceutically acceptable salt thereof, e.g. ##STR1## which are useful for inhibiting fibrinogen binding to blood platelets, thereby inhibiting platelet aggregation.
    Type: Grant
    Filed: March 9, 1999
    Date of Patent: September 12, 2000
    Assignee: Merck & Co., Inc.
    Inventors: George D. Hartman, Robert S. Meissner
  • Imidazopyridine thrombin inhibitors
    Patent number: 6093717
    Abstract: Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: ##STR1## wherein Y.sup.1 and Y.sup.2 are independently selected from the group consisting ofhydrogen,C.sub.1-4 alkyl,C.sub.1-4 alkoxy,C.sub.
    Type: Grant
    Filed: May 26, 1999
    Date of Patent: July 25, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Philip E. Sanderson, Adel M. Naylor-Olsen
  • Thrombin inhibitors
    Patent number: 6087373
    Abstract: A compound which inhibits human thrombin and which has the general structure ##STR1##
    Type: Grant
    Filed: September 21, 1998
    Date of Patent: July 11, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Craig Coburn, Joseph P. Vacca, Peter D. Williams
  • Anticoagulant test
    Patent number: 6063584
    Abstract: The present invention is a method for identifying a patient at risk to developing fibrinogen receptor antagonist-induced thrombocytopenia which comprises incubating patient plasma with a GPIIb/IIIa receptor:GPIIb/IIIa receptor antagonist complex to form a GPIIb/IIIa receptor:GPIIb/IIIa receptor antagonist:plasma antibody complex, incubating the GPIIb/IIIa receptor:GPIIb/IIIa receptor antagonist:plasma antibody complex with a secondary anti-human detectable antibody to form a GPIIb/IIIa receptor:GPIIb/IIIa receptor antagonist:plasma antibody:secondary anti-human detectable antibody complex, and detecting the presence of the secondary anti-human detectable antibody in the GPIIb/IIIa receptor:GPIIb/IIIa receptor antagonist:plasma antibody:secondary anti-human detectable antibody complex.
    Type: Grant
    Filed: November 21, 1997
    Date of Patent: May 16, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Bohumil Bednar, Robert J. Gould
  • Sulfonamide fibrinogen receptor antagonists
    Patent number: 6040317
    Abstract: A series of non-peptide derivatives that are antagonists of the fibrinogen IIb/IIIa receptor and thus are platelet anti-aggregation compounds useful in the prevention and treatment of diseases caused by thrombus formation.
    Type: Grant
    Filed: December 28, 1998
    Date of Patent: March 21, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Duggan, Wasyl Halczenko, Melissa S. Egbertson, George D. Hartman, William L. Laswell
  • Thrombin inhibitors
    Patent number: 6017934
    Abstract: A compound which inhibits human thrombin and where has the structure ##STR1##
    Type: Grant
    Filed: January 20, 1998
    Date of Patent: January 25, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Philip E. Sanderson, Terry A. Lyle, Craig Coburn
  • Pyrazinone thrombin inhibitors
    Patent number: 6011038
    Abstract: Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: ##STR1## for example: ##STR2##
    Type: Grant
    Filed: September 3, 1998
    Date of Patent: January 4, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Bruce D. Dorsey, Philip E. Sanderson, Terry A. Lyle
  • Thrombin inhibitors
    Patent number: 6004976
    Abstract: A compound which inhibits human thrombin and where has the structure ##STR1## such as ##STR2##
    Type: Grant
    Filed: December 1, 1998
    Date of Patent: December 21, 1999
    Assignee: Merck & Co., Inc.
    Inventor: Craig Coburn
  • Methods and compositions for preventing and treating heartburn
    Patent number: 5989588
    Abstract: A method for preventing heartburn episodes in a patient at risk to development of heartburn, comprising administering to the patient, following the heartburn inducing event but prior to development of heartburn, a composition comprising a pharmaceutically effective amount of an H.sub.2 antagonist and an amount of antacid having between about 15 mEq and 46 mEq acid neutralizing capacity.
    Type: Grant
    Filed: September 30, 1997
    Date of Patent: November 23, 1999
    Assignees: Merck & Co., Inc., McNeil-PPC, Inc.
    Inventors: Scott H. Korn, Gerard P. McNally, Joseph R. Luber, Tom S. Ells
  • Fibrinogen receptor antagonist prodrugs
    Patent number: 5990107
    Abstract: Fibrinogen receptor antagonist alcohol prodrugs having the structure, for example, of ##STR1## more particularly, ##STR2##
    Type: Grant
    Filed: June 26, 1997
    Date of Patent: November 23, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Melissa S. Egbertson, George D. Hartman, William C. Lumma, John S. Wai, Steven D. Young
  • Oral coated active drugs
    Patent number: 5980951
    Abstract: An oral drug dosage unit, for administration to a patient, having active drug, and an effective diameter and surface composition sufficient for the unit to be transported from the stomach into the duodenum following substantially complete emptying of chyme from the stomach into the intestine and prior to release of active drug from the unit, wherein the active drug has an absorption rate that is substantially affected by the coinciding presence of food in the stomach, the effective diameter of the unit prevents gastric emptying of the unit prior to gastric emptying of chyme, and the surface composition is an enteric coating which prevents release of the active drug in the stomach and allows release of the active drug in the intestine.
    Type: Grant
    Filed: April 8, 1997
    Date of Patent: November 9, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Colin R. Gardner, Mandana Asgharnejad
  • Fibrinogen receptor antagonist prodrugs
    Patent number: 5981584
    Abstract: Fibrinogen receptor antagonist prodrugs having the structure, for example, of ##STR1## more particularly, ##STR2##
    Type: Grant
    Filed: February 3, 1998
    Date of Patent: November 9, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Melissa S. Egbertson, Steve D. Young, George D. Hartman, Jacquelynn J. Cook
  • Angioplasty procedure using nonionic contrast media
    Patent number: 5978698
    Abstract: A method for treating patients in need of percutaneous transluminal coronary angioplasty which comprises administering nonionic contract media to the patient and treating the patient with a fibrinogen receptor antagonist.
    Type: Grant
    Filed: October 8, 1997
    Date of Patent: November 2, 1999
    Assignee: Merck & Co., Inc.
    Inventor: Frederic L. Sax
  • Compositions for inhibiting platelet aggregation
    Patent number: 5972967
    Abstract: The invention is a pharmaceutical composition for intravenous administration to a patient comprisinga) a pharmaceutically effective amount of 2-S-(n-Butylsulfonylamino)-3-[4-(4-(piperidin-4-yl)butyloxy)phenyl]propion ic acid;b) a pharmaceutically acceptable amount of a citrate buffer effective to provide a pH of between about 5 and 7; andc) a pharmaceutically acceptable amount of a tonicity adjusting agent effective to make the formulation substantially isotonic with the osmotic pressure of the biological system of the patient.
    Type: Grant
    Filed: November 7, 1997
    Date of Patent: October 26, 1999
    Assignee: Merck & Co., Inc.
    Inventor: Karl M. Gelotte
  • Compositions for inhibiting platelet aggregation
    Patent number: 5965581
    Abstract: A composition is disclosed comprising about 0.25 mg/ml 2-S-(n-Butylsulfonylamino)-3 -[4-(4-(piperdin-4-yl)butyloxylphenyl]propionic acid, about 8 mg/ml sodium chloride, about 2.7 mg/ml sodium citrate dihydrate, about 0.16 mg/ml citric acid anhydrous, wherein the composition osmolality concentration is between about 250-310 mOsmol/kg and the pH is in the range of between 5.5-6.5.
    Type: Grant
    Filed: May 15, 1998
    Date of Patent: October 12, 1999
    Assignee: Merck & Co., Inc.
    Inventor: Karl M. Gelotte
  • Integrin receptor antagonists
    Patent number: 5952306
    Abstract: Fibrinogen receptor antagonists having the formula ##STR1## for example ##STR2## which are useful for inhibiting the binding of fibrinogen to blood platelets and for inhibiting the aggregation of blood platelets.
    Type: Grant
    Filed: January 14, 1997
    Date of Patent: September 14, 1999
    Assignee: Merck & Co., Inc.
    Inventors: George D. Hartman, Mark E. Duggan, James J. Perkins, Cecilia A. Hunt, Amy E. Krause, John H. Hutchinson, Benny C. Askew, Karen M. Brashear, Nathan C. Ihle
  • Fibrinogen receptor antagonists
    Patent number: 5945545
    Abstract: Compounds of this invention have the formula: ##STR1## and pharmaceutically acceptable salts, e.g.
    Type: Grant
    Filed: December 11, 1997
    Date of Patent: August 31, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Melissa S. Egbertson, George D. Hartman, Laura M. Vassallo
  • Pyrazinone, pyridinone, piperidine and pyrrolidine thrombin inhibitors
    Patent number: 5932606
    Abstract: A compound which inhibits human thrombin and where has the structure and pharmaceutically acceptable salts thereof, wherein such as ##STR1## which are useful for inhibiting formation of blood platelet aggregates in blood in a mammal.
    Type: Grant
    Filed: March 20, 1998
    Date of Patent: August 3, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Richard C. A. Isaacs, Adel M. Naylor-Olsen, Bruce D. Dorsey, Christina L. Newton
  • Fibrinogen receptor antagonist prodrugs
    Patent number: 5932582
    Abstract: Fibrinogen receptor antagonist alcohol prodrugs having the structure, for example, ofX--W--Y--Z--A--Bmore particularly, ##STR1##
    Type: Grant
    Filed: June 26, 1997
    Date of Patent: August 3, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Steven D. Young, George D. Hartman, Laura A. Libby, Melissa S. Egbertson, Donald E. Slaughter
  • Guainidino, formamidino, amino and related compounds for inhibiting osteoclast-mediated bone resorption
    Patent number: 5929120
    Abstract: Compounds of the following general structureX--Y--Z-Aryl-A--B, ##STR1## which inhibit osteoclast mediated bone resorption.
    Type: Grant
    Filed: January 30, 1998
    Date of Patent: July 27, 1999
    Assignee: Merck & Co., Inc.
    Inventors: George D. Hartman, Mark E. Duggan, William F. Hoffman, Nathan C. Ihle